share_log

歐康維視生物-B:自願性公告OT-202的II期臨床試驗達到主要終點

OCUMENSION-B: VOLUNTARY ANNOUNCEMENTPRIMARY ENDPOINTS ACHIEVEDIN THE PHASE II CLINICAL TRIAL OF OT-202

Hong Kong Stock Exchange ·  Mar 14 00:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more